Pire SME, Sanchez BA

Language: Spanish
References: 15
Page: 203-207
PDF size: 175.56 Kb.

ABSTRACT

The diagnostics and treatment in patients with acute coronary syndrome (ACS) has evolved considerably during the last decade. Biomarkers play an important role in the diagnosis of ACS, specially in unstable angina and ST elevation myocardial infarction. Within the protein markers for coronary disease, troponin and creatine kinase appear to be the most sensitive and specific to myocardial damage. Recent studies have brought to light new biomarkers, but an ideal compound that allows for early detection, risk stratification, therapeutic selection and treatment efficacy has yet to be found. This review is designed to evaluate a set of cardiovascular biomarkers, their diagnostic, prognostic and therapeutic value in relation to acute coronary syndrome and some associated pathologies.

REFERENCES

1. Alvarez-Peréz F.J., Verde I. Fosfolipasa A2 asociada a lipoproteínas y patología vascular cerebral.Rev Neurol 2009; 49 (2): 88-94

2. Bardaj Alfredo, El papel de las troponinas en el diagnóstico y pronóstico de los Síndromes Coronarios Agudos. Rev Esp Cardiol Supl. 2005; vol 5: 19 C-25C.

3. Cassiani A. Carlos, Cabrera G Armando. Sindromes Coronarios Agudos: epidemiologia y diagnóstico. Salud Uninorte.2009; vol 25(1): 118-134.

4. Coronel L. Maria, Perna R. Eduardo y cols. Nuevos biomarcadores en los síndromes de insuficiencia cardiaca aguda y crónica. Rol de la lipocalina asociada a la gelatinasa de neutrófilos y el antígeno carbohidrato 125.Revista Fed Arg Cardiol. 2011; vol 40(4):410-414.

5. Cruz DN, Gaiao S, Maisel A. Neutrophil gelatinase-associated lipocalin as a biomarker of cardiovascular disease: a systemic review.Clin Chem Lab Med. 2012; vol 50(9): 1533-1545

6. Devaratan P. Neutrophil gelatinase associated Lipocalin: a promising biomarker for acute kidney injury. Crit Care Clin 2011, vol 27:379-389

7. Khuseyihova N, Imhof A. Association between Lp-PLA2 and coronary artery disease. Atherosclerosis 2005; 182:181-188

8. Lera S. Mariano, Mustafa E. Andres, García G. Susana y cols. Valoración de la utilidad del test detector de la proteína transportadora de ácidos grasos específica del miocardio (h-FABP) en los infartos agudos de miocardio diagnosticados en el medio extrahospitalario. Emergencias 2009, 21:333-338.

9. Lindberg S, Pedersen SH, Mogelvang R, Jensen JS. Utilidad pronostica de neutrófilos asociada a la gelatinasa lipocalina en la predicción de la mortalidad y los eventos cardiovasculares en pacientes con infarto con elevación del segmento ST tratados con intervención coronaria percutánea primaria. Am Coll Cardiol.2012;vol 60(4): 339-345

10. Mc Collough P, Cardiorenal Syndromes Pathophysiology to Prevention. J Nephrol 2010 , vol 1,2011

11. Minaña G, Palau P, Nuñez J, et al. The tumor marker CA 125 levels in patients with heart failure.Rev Esp Cardiol 2010, vol 63: 1213-1214.

12. Mockel M, Muller R. Lipoproteina associated phospholipase A2 for early risk stratification in patients with suspected acute coronary Syndrome.Clin Res Cardiol. 2007;vol 96:604-612.

13. Packard C, Reilly D .Lipoprotein associated Phospholipase A2 as an indepent predictor of Coronary Heart Disease. N Engl J Med 2000; vol 20:1148-1155

14. Pérez Surribas D, Cárdenas Fernández, M. y cols. Nuevos marcadores en el síndrome coronario agudo. Revista de laboratorio clínico 2009, vol 02:34-46

15. Ronco C, Collough P. Cardiorenal Syndromes report de consensus conference of the acute Dialysis Quality initiative. Eur Heart J 2010, vol 31 :703-711